Business Description
Co-Diagnostics Inc
NAICS : 325413
SIC : 5047
ISIN : US1897631057
Share Class Description:
HAM:C970: Registered ShsTotal Employee Number:
115Description
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.05 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.07 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -11.97 | |||||
Beneish M-Score | -2.2 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -75.7 | |||||
3-Year EBITDA Growth Rate | -32.2 | |||||
3-Year EPS without NRI Growth Rate | -41.2 | |||||
3-Year Book Growth Rate | -55.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 28.54 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 451.31 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 24.53 | |||||
14-Day RSI | 33.14 | |||||
6-1 Month Momentum % | -0.54 | |||||
12-1 Month Momentum % | -19.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.28 | |||||
Quick Ratio | 2.09 | |||||
Cash Ratio | 1.92 | |||||
Days Inventory | 944.18 | |||||
Days Sales Outstanding | 68.63 | |||||
Days Payable | 1797.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -26.7 | |||||
Shareholder Yield % | -136.86 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 45.13 | |||||
Operating Margin % | -4448.47 | |||||
Net Margin % | -6755.29 | |||||
EBITDA Margin % | -4297.63 | |||||
FCF Margin % | -4049.68 | |||||
OCF Margin % | -3944.48 | |||||
ROE % | -146.48 | |||||
ROA % | -125.92 | |||||
ROIC % | -127.93 | |||||
3-Year ROIIC % | 76.48 | |||||
ROC (Joel Greenblatt) % | -783.04 | |||||
ROCE % | -92.85 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6.41 | |||||
PB Ratio | 0.67 | |||||
Price-to-Tangible-Book | 1.23 | |||||
EV-to-EBIT | -0.15 | |||||
EV-to-EBITDA | -0.16 | |||||
EV-to-Revenue | 6.76 | |||||
EV-to-Forward-Revenue | 4.81 | |||||
EV-to-FCF | -0.17 | |||||
Price-to-GF-Value | 1.4 | |||||
| Price-to-Net-Current-Asset-Value | 2.5 | |||||
| Price-to-Net-Cash | 3.91 | |||||
Earnings Yield (Greenblatt) % | -666.67 | |||||
FCF Yield % | -262.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Co-Diagnostics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.616 | ||
| EPS (TTM) (€) | -27.803 | ||
| Beta | 1.2487 | ||
| 3-Year Sharpe Ratio | -0.55 | ||
| 3-Year Sortino Ratio | -0.7 | ||
| Volatility % | 76.11 | ||
| 14-Day RSI | 33.14 | ||
| 14-Day ATR (€) | 0.000043 | ||
| 20-Day SMA (€) | 5.55 | ||
| 12-1 Month Momentum % | -19.57 | ||
| 52-Week Range (€) | 5.55 - 30.3 | ||
| Shares Outstanding (Mil) | 3.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Co-Diagnostics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Co-Diagnostics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 137 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 136 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 16:30 | In 46 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 45 days | ||
| General meeting for 2026 | 2026-07-02 | In 2 days | ||
| First quarter earnings conference call for 2026 | 2026-05-14 16:30 | 5.55 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 5.55 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-31 16:30 | 5.55 (+0.00%) | ||
| Annual report for 2025 | 2026-03-31 | 5.55 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 5.55 (+0.00%) |
Show
Entries
Co-Diagnostics Inc Frequently Asked Questions
What is Co-Diagnostics Inc(HAM:C970)'s stock price today?
The current price of HAM:C970 is €5.55. The 52 week high of HAM:C970 is €30.30 and 52 week low is €5.55.
When is next earnings date of Co-Diagnostics Inc(HAM:C970)?
The next earnings date of Co-Diagnostics Inc(HAM:C970) is 2026-08-14 Est..
Does Co-Diagnostics Inc(HAM:C970) pay dividends? If so, how much?
Co-Diagnostics Inc(HAM:C970) does not pay dividend.
Press Release
Articles on Co-Diagnostics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers